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Abstract
Background: Few studies reported the associations between decreased glomerular filtration rate (GFR) and mortality,
coronary heart disease (CHD), and stroke in hypertensive patients. We aim to assess the associations between GFR and
mortality, CHD, and stroke in hypertensive patients and to evaluate whether low GFR can improve the prediction of these
outcomes in addition to conventional cardiovascular risk factors.
Methods and Findings: This is an observational prospective study and 3,711 eligible hypertensive patients aged $5 years
from rural areas of China were used for the present analysis. The associations between eGFR and outcomes, followed by a
median of 4.9 years, were evaluated using Cox proportional hazards models adjusting for other potential confounders. Low
eGFR was independently associated with risk of all-cause mortality, cardiovascular mortality, and incident stroke
[multivariable adjusted hazard ratios (95% confidence intervals) for eGFR ,60 ml/min/1.73 m
2 relative to eGFR $90 ml/
min/1.73 m
2 were 1.824 (1.047–3.365), 2.371 (1.109–5.068), and 2.493 (1.193–5.212), respectively]. We found no
independent association between eGFR and the risk of CHD. For 4-year all-cause and cardiovascular mortality, integrated
discrimination improvement (IDI) was positive when eGFR were added to traditional risk factors (1.51%, P=0.016, and
1.99%, P=0.017, respectively). For stroke and CHD events, net reclassification improvements (NRI) were 5.9% (P=0.012) and
1.8% (P=0.083) for eGFR, respectively.
Conclusions: We have established an inversely independent association between eGFR and all-cause mortality,
cardiovascular mortality, and stroke in hypertensive patients in rural areas of China. Further, addition of eGFR significantly
improved the prediction of 4-year mortality and stroke over and above that of conventional risk factors. We recommend
that eGFR be incorporated into prognostic assessment for patients with hypertension in rural areas of China.
Limitations: We did not have sufficient information on atrial fibrillation to control for the potential covariate. These
associations should be further confirmed in future.
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Introduction
The clinical spectrum of chronic kidney disease (CKD) ranges
from an unnoticed decrease in glomerular filtration rate (GFR) to
end-stage renal failure (ESRD). Individuals with ESRD have a
cardiovascular disease (CVD) mortality rate that is 10 to 20 times
greater than that in the general population [1,2,3]. It has also
been demonstrated that decreased GFR is associated with
increased all-cause and CVD mortality, incident coronary heart
disease (CHD) in general population [1,4], individuals with
manifest arterial disease [5], and high-risk of vascular events [6].
However, few studies reported the associations in patients with
hypertension.
Stroke remains the leading cause of disability and second
leading cause of death globally. Many factors have been
recognized to be independently associated with risk of stroke,
which included history of hypertension, current smoking, diabetes
mellitus, alcohol intake, atrial fibrillation (AF), and so on.
However, it remains uncertain whether reduced GFR constitutes
an independent predictor of stroke. In a pooled analysis of
community-based studies, estimated GFR ,60 ml/min/1.73 m
2
is not at increased risk of stroke in general population [1]. A recent
analysis from PROSPER (Prospective study of Pravastatin in the
Elderly at Risk) reported on this association showed a small and
nonsignificant increase in stroke risk with decreasing GFR in
elderly people [6], and the impact of reduced GFR was shown to
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2 diabetes mellitus [7,8]. In the Rotterdam study, Bos et al. [9]
highlighted that decreased GFR is a strong risk factor for
hemorrhage, but not for ischemic stroke in general population.
A large cross-sectional study of older adults showed an association
of low GFR with prior stroke [10], however this has not been
intensively borne out in prospective cohorts [11].
In summary, in hypertensive patients, there is a relative scarcity
evaluating the associations between the reduced GFR with
mortality and CHD, especially with stroke in prospective cohorts.
Therefore, we selected a representative sample of hypertensive
patients in rural areas of China to assess these associations and to
evaluate whether low GFR can improve the prediction of these
outcomes in addition to conventional CVD risk factors.
Methods
Study design and sample
This is a large-scale epidemiological prospective study. From
2004 to 2006, a multistage, random cluster sampling design was
performed to select a representative sample of the rural population
with hypertension aged 35 years and older from 50 rural villages of
Liaoning Province. The detailed methodology was described
elsewhere [12]. In 2010, investigators were invited to participate
the follow-up study. Of the 6,104 patients with hypertension at
baseline, 634 were not included the follow-up study because study
participants’ contact information was unavailable. Overall, 5,470
aged $35 years at their baseline examination were eligible to
participate in the follow-up study. From this population, a total of
4,945 study participants (90.4%) (or their guardians) were
identified and agreed to be interviewed as part of the follow-up
study. For the present study, hypertensive patients with missing
baseline serum creatinine (SCr) (n=776) and serum uric acid
(n=95), with and having stroke (n=294) and coronary heart
disease (CHD) (n=69) at baseline were excluded, leaving 3,711
data from hypertensive patients free CVD at baseline for the
present analyses. Figure 1 shows the sample size of patients and
exclusion reasons in our study.
Ethical approval, informed consent and patient privacy
The study complies with the Declaration of Helsinki. China
Medical University Research Ethics Committee has approved the
research protocol and that written informed consent has been
formally obtained from all patients or their guardians. Patients
who agreed to participate were explained the content of informed
consent which included the purpose of the study, medical items,
and confidentiality agreement of personal information. The
information about patient’s identity was not included with the
other data and only the principal investigator had access to this
information. No reference to the patient’s identity was made at
any stage during data analysis or in the paper.
Glomerular filtration rate assessment
Subjects were asked to fast for at least 12 hours before blood
collection. Blood samples were obtained from an antecubital vein
into vacutainer tubes containing EDTA. Blood chemical analyses
were performed at a central, certified laboratory. SCr was
measured by the kinetic alkaline picrate (Jaffe ´) method on an
Olympus AU640 autoanalyzer (Olympus, Kobe, Japan). The
GFR was estimated using the equation that originated from the
CKD Epidemiology Collaboration (CKD-EPI) equation [13],
which is more accurate than the equation form the Modification of
Diet in Renal Disease (MDRD) Study group equation [14].
Patients were divided into the following three categories by
eatimated GFR (eGFR) at baseline:$90 (n=1,625), 60 to 90
(n=1,967), and ,60 (n=119) ml/min/1.73 m
2.
Data collection and physical examinations at baseline
At baseline examination, all participants were recruited and
examined at a single clinic visit by their local doctors in their
geographical area of origin from 2004 to 2006. There was a
central steering committee with a subcommittee for quality
control. Before the survey was performed, the research staff had
trained the local doctors, which included the purpose of this
research, how to administer the questionnaire, the method of
measurement, and the study procedures. A strict test was
conducted after the training, only those who scored perfectly on
the test could become investigators. During data collection, our
inspectors had further instructions and support.
Data on demographic variables (age, sex, and ethnicity),
smoking status, use of alcohol, information on antihypertensive
medications, lipid-lowering drug use, and history of stroke and
CHD at baseline were obtained by interviews with a standard
epidemiological questionnaire. Drinking status was assessed by
alcohol consumption which defined as the weekly consumption of
beer, wine and hard liquor converted into grams of alcohol.
Alcohol drinker was defined as alcohol consumption at least 8
grams per week during the last year [15]. Current smoking was
defined as people who smoked at least one cigarette every day and
continued for at least one year. Smoking was assessed as part of the
questionnaire. The individuals were asked whether they currently
smoked or not (Do you smoke currently?). Body weight and height
were measured with subjects wearing light clothing and without
shoes according to a standard protocol. History of stroke or CHD
at baseline was positive if a stroke or CHD was reported during the
baseline interview and confirmed by medical records. Body mass
index (BMI) was calculated by the weight in kilograms divided by
height in square meters. Diabetes mellitus was defined as fasting
serum glucose levels $7.0 mmol/l or plasma glucose concentra-
tion of $11.0 mmol/l2 h after a 75-g oral glucose load or current
treatment with insulin or oral hypoglycaemic agents.
Blood Pressure (BP) was measured using a standardized
automatic electronic sphygmomanometer (HEM-741C; Omron,
Tokyo, Japan). A trained and certified observer used an American
Heart Association protocol to perform three BP measurements
after study participants had been seated quietly for 5 minutes.
Participants were instructed to avoid alcohol consumption,
cigarette smoking, coffee/tea, and exercise for at least 30 minutes
before these measurements. The mean of 3 BP measures was
calculated and used in all analysis. Participants with hypertension
at baseline was defined as they had an average systolic BP
$140 mmHg, and/or an average diastolic BP $90 mmHg, and/
or use of antihypertensive medication within the previous 2 weeks.
Serum glucose, uric acid, total cholesterol, and high-density
lipoprotein cholesterol (HDL-C) were measured in fasting baseline
serum with automated enzymatic procedure.
Follow-up time and outcomes
The follow-up examination was conducted from July to October
2010. Deaths were identified through hospital records and directly
contact with their families. Using the International Classification
of Diseases, 9th Revision (ICD-9), Clinical Modification [16],
deaths due to CVD were assigned a code from 400 through 444
including CHD, stroke, and others. We confirmed that death from
CVD on the basis of autopsy reports, death certificates, medical
record abstractions, or information obtained from family mem-
bers.
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longer than 24 hours or resulting in death within 24 hours of the
onset of symptoms, and was diagnosed as being due to cerebral
lesions of vascular origin. Most stroke cases (n=167, 90.3%) were
diagnosed by computed tomography, MRI including diffusion
image, magnetic resonance angiography of the brain and carotid
duplex imaging. CHD was defined as myocardial infarction,
angina pectoris of which patients received treatment in hospital for
ischemic discomfort and diagnose by coronary angiography,
coronary revascularization and sudden death. Coronary revascu-
larization was achieved when a patient underwent percutaneous
coronary intervention (for example, angioplasty, stenting, ather-
ectomy and laser ablation) or coronary artery bypass graft. The
information was obtained by direct reference to medical records
by a single investigator.
All materials were independently reviewed by the end-point
assessment committee and all members of the end-point
assessment committee were blinded to the study participant’s
baseline risk factor information.
Statistical analysis
The rates of events are presented as the number of events per
1,000 patient-years, based on the ratio of the number of events
observed to the total number of patient-years of exposure up to the
terminating event or censor. The rates of events by baseline eGFR
subgroups ($90, 60–90, and ,60 ml/min/1.73 m
2) were tested
by Cochran-Armitage Trend Test. We used Cox proportional
hazards models to calculate hazard ratios (HRs) with 95%
confidence intervals (CI) for the associations between eGFR and
incident events. HRs was calculated for eGFR categories, with the
eGFR $90 ml/min/1.73 m
2 as the reference group. We
constructed 2 models: in model 1, we adjusted for age, sex, and
Mongolian ethnicity; and in model 2, we adjusted for age, sex,
Mongolian ethnicity, and a propensity score. We calculated the
propensity score with a linear regression model entering eGFR as
the dependent variable and the independent variables included
systolic BP, diastolic BP, pulse rate, BMI, antihypertensive drug
use, current smoking, current drinking, diabetes mellitus, serum
uric acid, total cholesterol, HDL-C, and lipid-lowering drug use.
The proportionality assumption was evaluated by scaled Schoen-
feld residuals, and the global fit of the models was evaluated by
graphically examining the cumulative hazards function relative to
the Cox-Snell residuals.
Furthermore, a logistic regression score was established for 4-
year events when we fixed the duration of follow-up to 48 months.
With fatal events, stroke, and CHD as the end points, two
consecutive logistic models of increasing saturation were per-
formed containing (1) age, sex, Mongolian ethnicity,systolic BP,
diastolic BP, pulse rate, BMI, antihypertensive drug use, current
smoking, current drinking, diabetes mellitus, serum uric acid, total
cholesterol, HDL-C, and lipid-lowering drug use, and (2) eGFR
added. To estimate the increase in prediction accuracy, we used
Figure 1. Flow chart of participant recruitment and derivation of the population used in the final analysis.
doi:10.1371/journal.pone.0027359.g001
GFR with Risk of Mortality and CVD
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27359the logistic regression score to calculate the area under the
receiver-operator characteristic curves (AUC) and compared the
AUC based on the models without and with eGFR [17]. We also
estimated the integrated discrimination improvement (IDI) (18),
which is the difference in an R
2-like statistic between the
traditional and expanded models. Net reclassification improve-
ment (NRI), which examines the net effect of adding a marker to
the risk prediction scheme using a statistic described by Pencina
et al [18], was computed for stroke and CHD events, but not for
all-cause and CVD mortality as no predefined thresholds for low,
intermediate, or high risk have been published. The reclassifica-
tion categories were defined as ,1%, 1% to 5%, 5% to 20%,
$20% for 4-year stroke risk and ,5%, 5% to 10%, 10% to 20%,
20% for 4-year CHD risk. Finally, reclassification calibration
statistics (RCS) was also calculated to evaluate model calibration.
A significant result indicates a lack of fit.
All analyses were performed with SPSS statistical software
version 12.0 (SPSS Inc., Chicago, IL, USA). A P value less than
0.05 was accepted as indicating statistical significance.
Results
The median age of the participants of the present study was 56
years (range: 35–91 years) and 2,123 (57.2%) were women. The
median of serum creatinine and eGFR were 73.9 mmol/L and
87.6 ml/min/1.73 m
2, respectively. There were 119 (3.2%)
patients with eGFR ,60, 1,967 (53.0%) patients with eGFR 60
to 90, and 1,625 (43.8%) patients with eGFR $90 ml/min/
1.73 m
2, respectively. Other baseline characteristics are described
in Table 1. The 2,393 patients who were not included in the
present study relative to the included participants (n=3,711) have
the similar age (median: 57 versus 56 years; P=0.225), systolic BP
(median: 157 versus 160 mmHg; P=0.507), diastolic BP (median:
96 versus 95 mmHg; P=0.783), and more likely to be female
(61.3% versus 57.2%, P=0.002).
At the time of follow-up examination, 1,446 patients (39.0%)
were receiving antihypertensive medications (compound reserpine,
n=763; diuretic, n=418; calcium antagonist, n=703; angioten-
sin-converting enzyme inhibitor, n=637; and angiotensin recep-
tors antagonist, n=64). During on median 4.9 years (range: 3.7 to
6.5 years) of follow-up, a total of 202 patients had died and 133
deaths were attributable to CVD. Mortality from all-cause and
CVD were 11.47 (95% CI, 9.90 to 13.04) and 7.55 (95% CI, 6.27
to 8.83) per 1,000 patient-years, respectively. Meanwhile, 185 first-
ever stroke and 102 first-ever CHD occurred during follow-up and
the incident rates of stroke and CHD were 10.75 (95% CI, 9.21 to
12.29) and 5.79 (95% CI, 4.67 to 6.91) per 1,000 patient-years,
respectively.
Figure 2 shows the rates and their 95% CI of all-cause
mortality, CVD mortality, incident stroke, and CHD according to
eGFR categories. As expected, there was an inverse association
between eGFR and incident events (P for trend ,0.001 each):
compared with patients with an eGFR $90 ml/min/1.73 m
2,
patients with an eGFR ,60 ml/min/1.73 m
2 had a more than 6-
fold increase in all-cause or CVD mortality and a more than 4-fold
increase in incident stroke or CHD. After adjustment for sex, age,
and Mongolian ethnicity, patients with eGFR ,60 ml/min/
1.73 m
2 versus eGFR $90 ml/min/1.73 m
2 had HRs of 2.014
(95% CI, 1.105 to 3.670) for all-cause mortality, 2.784 (95% CI,
Table 1. Baseline characteristics of study participants (n=3,711).
Baseline characteristics Median* or Percentage Association with eGFR{
b coefficient P value
Age, years 56 (49264) 20.810 ,0.001
Women, n (%) 2,123, 57.2 28.156 ,0.001
Mongolian, n (%) 752, 20.3 1.226 0.001
Systolic blood pressure, mmHg 160 (1462178) 20.010 0.269
Diastolic blood pressure, mmHg 95 (892103) 20.072 ,0.001
Pulse rate, beats/min 75 (69282) 0.016 0.284
Body mass index, kg/m
2 23.74 (22.03225.95) 0.059 0.237
Current smoking, n (%) 1,443, 38.9 0.271 0.491
Alcohol drinking, n (%) 1021, 27.5 1.376 0.003
Diabetes mellitus, n (%) 426, 11.5 20.898 0.076
Serum uric acid, mmol/L 256.4 (212.22307.0) 20.054 ,0.001
Total cholesterol, mmol/L 5.18 (4.5425.84) 20.017 0.935
HDL-C, mmol/L 1.39 (1.1921.60) 0.298 0.657
Antihypertensive medication, n (%) 1,446, 39.0 20.087 0.798
Lipid-lowering drug use, n (%) 101, 2.7 20.024 0.981
Serum creatinine, mmol/L 73.9 (66.8282.2) - -
eGFR, ml/min/1.73 m
2 87.6 (78.2297.0) - -
,60, n (%) 119, 3.2 - -
60–90, n (%) 1,967, 53.0 - -
$90, n (%) 1,625, 43.8 - -
*With 25th and 75th percentiles.
{b coefficients and P values estimated with linear regression model adjusted for all other characteristics.
HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate.
doi:10.1371/journal.pone.0027359.t001
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for incident stroke, and 1.917 (95% CI, 0.787 to 4.668) for
incident CHD, respectively. Further adjustment for the propensity
score of all potential confounders hardly attenuated the HRs. In
addition, patients with 60# eGFR ,90 ml/min/1.73 m
2 versus
eGFR $90 ml/min/1.73 m
2 had a HR of 2.294 (95% CI, 1.532
to 3.437) for incident stroke after adjustment for gender, age, and
Mongolian ethnicity and the corresponding HR is 2.047 (95% CI,
1.359 to 3.082) after further adjustment for the propensity score
(Table 2). There was no evidence of significant interaction
between putative confounders and eGFR in predicting each study
outcome. No violations of the Cox proportional hazards
assumption were observed.
When we fixed the duration of follow-up to 4 years, the number
of eligible patients were 3,646 [eGFR (ml/min/1.73 m
2: ,60,
n=111; 60–90, n=1,931; $90, n=1,604]. Of those, there were
147 all-cause deaths, 94 CVD deaths, 135 incident stroke, and 41
incident CHD. With the mortality, stroke, and CHD as the end
points, two consecutive logistic models were separately performed.
Adding eGFR to the model based on conventional risk factors to
predict mortality resulted in positive IDI, whereas improvements
in the AUC were no significant (Table 3). Upon adding eGFR to
the model based on conventional risk factors for 4-year stroke risk
assessment, IDI and NRI, but not AUC, indicated discrimination
improvement. For stroke risk assessment, RCS yield a chi-square
of 13.463 (P=0.019) for the model without eGFR. This value
decreased to 10.065 (P=0.073) when eGFR were entered into the
model (Table 3). For CHD risk assessment, adding eGFR to the
model based on conventional risk factors, no discrimination
improvement was indicated.
Discussion
The present study revealed an inverse association between eGFR
and risk of all-cause and CVD mortality, and incident stroke, but not
CHD in hypertensive patients in rural areas of China. Compared
with the patients with eGFR $90 ml/min/1.73 m
2, patients with
60# eGFR ,90 ml/min/1.73 m
2 also carried a substantially
increased risk of incident stroke. The predictive value of eGFR
remained after adjustment for traditional CVD risk factors. In
addition, adding eGFR to the model based on conventional risk
factors for 4-year all-cause mortality, CVD mortality, and incident
stroke risk assessment indicated discrimination improvement.
In the past, few studies reported the association between eGFR
and stroke, and most of these studies have the negative results. In a
pooled analysis of 4 population-based studies, participants with
CKD was associated with a HR for stroke of 1.17 (95%CI, 0.95 to
1.44; P=0.13) [1]. In another study, the risk of stroke was
moderately increased in the lowest GFR quintile compared with
the highest GFR quintile with a 92% increased risk among
participants with GFR below the 7th percentile. This effect largely
disappeared after adjustment for confounding [19]. In our study,
there is a strong association between eGFR and stroke in
hypertensive patients. The risk of stroke increased by 149.3%
among patients with eGFR ,60 ml/min/1.73 m
2, compared with
patients with eGFR $90 ml/min/1.73 m
2. Furthermore, the
Figure 2. The rates and 95% confidence intervals of all-cause mortality (a), CVD mortality (b), stroke (c), and CHD (d) in patients
with hypertension according to eGFR categories. CVD, cardiovascular disease; CHD, coronary heart disease, eGFR, estimated glomerular
filtration rate.
doi:10.1371/journal.pone.0027359.g002
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2 also carried a
substantial risk of stroke. The predictive value of decreased eGFR
remained after adjustment for traditional CVD factors, although
some of the risk of CKD is due to its association with traditional
vascular factors. To our best of knowledge, this is the first study to
obtain the positive association between eGFR and stroke in
Table 2. HRs for the association between eGFR and risk of all-cause mortality, CVD mortality, incident stroke, and incident CHD in
patients with hypertension (n=3,711).
Endpoints n, HR, and P2value eGFR, ml/min/1.73 m
2
P for trend
P for eGFR
60–90 vs. ,60
$90 (n=1,625) 60–90 (n=1,967) ,60 (n=119)
All-cause mortality n (%) 48 (3.0%) 131 (6.7%) 23 (19.3%)
Model 1* HR (95%CI), P2value 1.000 1.043 (0.70321.547), 0.834 2.014 (1.10523.670), 0.022 P=0.073 P=0.016
Model 2{ HR (95%CI), P2value 1.000 0.989 (0.66321.475), 0.956 1.824 (1.04723.365), 0.044 P=0.145 P=0.032
CVD mortality n (%) 27 (1.7%) 90 (4.6%) 16 (13.4%)
Model 1* HR (95%CI), P2value 1.000 1.384 (0.83722.288), 0.205 2.784 (1.32225.862), 0.007 P=0.013 P=0.027
Model 2{ HR (95%CI), P2value 1.000 1.270 (0.76322.113), 0.358 2.371 (1.10925.068), 0.026 P=0.042 P=0.059
Incident stroke n (%) 40 (2.5%) 133 (6.8%) 12 (10.1%)
Model 1* HR (95%CI), P2value 1.000 2.294 (1.53223.437), ,0.001 3.127 (1.51326.462), 0.002 P,0.001 P=0.265
Model 2{ HR (95%CI), P2value 1.000 2.047 (1.35923.082), 0.001 2.493 (1.19325.212), 0.015 P=0.001 P=0.471
Incident CHD n (%) 28 (1.7%) 65 (3.3%) 9 (7.6%)
Model 1* HR (95%CI), P2value 1.000 1.147 (0.67821.939), 0.609 1.917 (0.78724.668), 0.152 P=0.244 P=0.190
Model 2{ HR (95%CI), P2value 1.000 1.024 (0.60121.744), 0.931 1.530 (0.61823.787), 0.358 P=0.516 P=0.299
*Model 1: adjusted for age, sex, and Mongolian ethnicity.
{Model 2: adjusted for age, sex, Mongolian ethnicity, and a propensity score (systolic blood pressure, diastolic blood pressure, pulse rate, body mass index,
antihypertensive drug use, current smoking, current drinking, diabetes mellitus, serum uric acid, total cholesterol, HDL-C, and lipid-lowering drug use).
HR, hazard ratio; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; CHD, coronary heart disease.
doi:10.1371/journal.pone.0027359.t002
Table 3. AUC, IDI, NRI, and RCS for the combined assessment of eGFR and traditional risk factors in predicting mortality, incident
stroke, and CHD.
AUC IDI NRI RCS
All-cause mortality
Model 1* 0.876 (0.854–0.898), P,0.001 / - -
Model 2{ 0.883 (0.862–0.905), P,0.001 1.51% - -
P value vs. model 1 0.525 0.016 - -
CVD mortality
Model 1* 0.873 (0.846–0.900), P,0.001 / - -
Model 2{ 0.885 (0.858–0.911), P,0.001 1.99% - -
P value vs. model 1 0.374 0.017 - -
Incident stroke
Model 1* 0.707 (0.662–0.752), P,0.001 / / x
2=13.463, P=0.019
Model 2{ 0.726 (0.683–0.770), P,0.001 0.91% 5.9% x
2=10.065, P=0.073
P value vs. model 1 0.399 0.024 0.012 -
Incident CHD
Model 1* 0.887 (0.850–0.925), P,0.001 / / x
2=2.958, P=0.398
Model 2{ 0.891 (0.856–0.926), P,0.001 0.30% 1.8% x
2=2.803, P=0.423
P value vs. model 1 0.829 0.438 0.823 -
*Variables included age, sex, Mongolian ethnicity, systolic blood pressure, diastolic blood pressure, pulse rate, body mass index, antihypertensive drug use, current
smoking, current drinking, diabetes mellitus, serum uric acid, total cholesterol, HDL-C, and lipid-lowering drug use.
{Model 1 + eGFR.
eGFR, estimated glomerular filtration rate; AUC, area under the curve; IDI, integrated discrimination improvement; NRI, net reclassification improvement; RCS,
reclassification calibration statistic; CVD, cardiovascular disease; CHD, coronary heart disease.
NRI and RCS computed for incident stroke and CHD only, because the lack of established thresholds of risk for all-cause and CVD mortality.
doi:10.1371/journal.pone.0027359.t003
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noteworthy supplement. These different results may be related
to the fact that the rate of incident stroke in these studies was lower
than in our study.
Mortality and cardiovascular events have strongly been
associated with decreased eGFR in community-based studies
(subjects considered at low risk) as well as in patients with
cardiovascular risk factors (high risk) or in selected patients with
established cardiovascular disease (highest risk) [1,4,19,20,21,22].
In a pooled analysis of community-based studies, subjects with
CKD (eGFR: 15 to 60 ml/min/1.73 m
2) had a 36% excess risk
for all-cause mortality compared with subjects with eGFR
$60 ml/min/1.73 m
2 (HR 1.36, 95% CI 1.21–1.53) [1]. Liesbeth
Bax et al. [5] indicated that the HRs of an estimated GFR #60
versus .90 ml/min/1.73 m
2 were 1.8 (95% CI, 1.2–2.6) for
vascular events and 1.4 (95% CI 0.9–2.0) for all-cause death. In a
diabetes population, a reduced eGFR was a significant risk factor
for CHD [7,8]. A baseline GFR of less than 53 ml/min/1.73 m
2
(compared with .104 ml/min/1.73 m
2) was independently
associated with a 32% higher risk for CHD in older high-risk
patients with hypertension [23]. Viazzi F et al [24] indicated that
renal dysfunction is a risk factor for CVD events and all-cause
mortality, regardless of traditional confounders, in uncomplicated
patients with primary hypertension. In accordance with these
results, we found that hypertensive patients with eGFR ,60 ml/
min/1.73 m
2 also carried an independently increased risk for all-
cause mortality (HR, 1.824) and CVD mortality (HR, 2.371),
compared with subjects with eGFR $90 ml/min/1.73 m
2.
However, we found no independent association between eGFR
and CHD in hypertensive patients in rural areas of China, which is
different from previous reports. One possible reason was that the
low rate of incident CHD in this rural population and few CHD
events accrued, reducing the statistical power of our analyses. In
addition, the different duration of follow-up and ethnical groups
may partly explain the disparity from other studies.
In most studies, including ours, adjustment for CVD risk factors
did not markedly change the associations between eGFR and the
risk of adverse outcomes [1,4,25,26,27], which means either that
eGFR is a better marker for vascular pathology than other
vascular risk factors or that decreased eGFR is a causal factor in
the pathogenesis of mortality and stroke. On the other hand, the
adjusted estimates may be underestimations of the true associa-
tions because at least part of the presumed effect of impaired renal
function on CVD is through the risk factors that were adjusted for.
Multiple explanations exist as to why the decreased eGFR may
be associated with an increased risk for mortality and stroke
events. GFR is a useful measure of overall kidney function in
health and disease. A decrease in kidney function may be
associated with an increase in other nontraditional risk factors
that were not included in the current analysis, including
hyperhomocysteinemia, inflammation, and oxidative stress [28].
In addition, reduced kidney function may be a marker for both
duration and severity of other causes of stroke, such as diabetes,
and thereby reflect residual confounding from these risk factors.
Furthermore, patients with kidney disease likely receive less
aggressive therapy for risk-factor modification [17,26,29].
It is important to determine whether a decreased eGFR
provides additional risk information over and above the
assessment of conventional cardiovascular risk factors. In the
present study, consecutive multiple regression models and the
measurements of discrimination improvement revealed that upon
adding eGFR into the model based on conventional cardiovascu-
lar risk factors resulted in a significant improvement in its
predictive value of 4-year risk of mortality and stroke. In our
study, adding eGFR to model based conventional risk factors
resulted in 5.9% of patients were reclassified into new stroke risk
categories, which may benefit the most by being placed into a
higher risk category for intervention with secondary prevention
measures.
Some limitations should also be considered in light of these
results. Firstly, the limitation of the study is the small number of
patients with an eGFR ,60 ml/min/1.73 m
2 (n=119, 3.2%) and
as a consequence, the number of events are very small, which may
induce the possible imprecise estimates and limited external
validity of findings. Secondly, the study subjects derived from a
previous study in rural areas of China and the lack of almost 20%
of baseline creatinin levels may implicate some selection bias. Our
results may not extrapolate to other populations, and further study
is warranted in more ethnically diverse populations. Thirdly,
serum creatinine is influenced by nonrenal factors and additional
measurement of urinary albumin might intermediate the causal
role of eGFR in adverse CVD outcomes. However, urinary
albumin was not measured in our study. Finally, AF is an
independent risk factor for stroke. It is associated with 4–5-fold
higher risk than in the unaffected population [30]. Also, 15% of all
strokes and 25% of strokes in patients .80 years old are
attributable to AF. In addition, AF is one modifiable risk factor
for stroke; it is strongly associated with an elevation of stroke risk
that can be greatly diminished using antithrombotic therapy.
However, we did not have sufficient information on concomitant
AF or concomitant oral anticoagulation/ASS therapy to control
for these potential covariates. Further study controlling for the
potential covariates (AF and anticoagulation/ASS therapy) to
evaluate the eGFR and stroke is encouraged in future.
In conclusion, the decreased eGFR is an independent risk factor
for adverse mortality, CHD, and stroke in patients with hypertension
in rural areas of China. The presence of vascular disease and other
risk factors did not alter the results. Addition of eGFR significantly
improved the prediction of 4-year mortality and incident stroke over
and above that of conventional risk factors. We strongly recommend
that eGFR be incorporated into prognostic assessment of patients
with hypertension in rural areas of China.
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